ArticleCureus2026
Description of Endobronchial Ultrasound-Guided Transbronchial Mediastinal Cryobiopsy for Mediastinal Lesions: A Real-World Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBNC) enables the acquisition of larger and higher-quality tissue samples than conventional endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA); however, evidence regarding its use and outcomes in Latin America remains limited. This retrospective observational study describes the clinical and procedural characteristics, the frequency of diagnosis obtained by histopathology, and the safety of patients subjected to EBUS-TBNC between June 2023 and December 2025. A total of 118 patients were included; 50.4% were female, and the mean age was 59.6 ± 17.8 years. Initial diagnosis was the main procedural indication (82.2%), and 79.7% of procedures targeted mediastinal lymph nodes, with station 7 being the most frequently biopsied (71.2%). A definitive histopathological diagnosis was obtained in 92.4% (109/118) of patients. The most common complications were pneumomediastinum (11.9%), bronchospasm (5.9%), and pneumothorax (4.2%), with no hemomediastinum or infectious complications reported. Lymphoma was the most frequent neoplasm (27.9%), whereas anthracosis was the predominant benign diagnosis (14.4%). Molecular testing was feasible, with PD-L1 (programmed death-ligand 1) being the most frequently assessed biomarker (37.3%). These findings suggest that EBUS-TBNC is a valuable technique for obtaining tissue suitable for comprehensive histopathological and molecular assessment, supporting its use in the diagnostic evaluation of mediastinal lesions. Its safety profile was characterized predominantly by non-severe complications, supporting its potential role as a diagnostic tool for mediastinal lesions, particularly in clinical scenarios where larger tissue samples are required, such as the evaluation of lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.